Selected article for: "cell surface and different protein"

Author: Kangro, K.; Kurashin, M.; Gildemann, K.; Sankovski, E.; Zusinaite, E.; Lello, L. S.; Pert, R.; Kavak, A.; Poikalainen, V.; Lepasalu, L.; Kuusk, M.; Pau, R.; Piiskop, S.; Rom, S.; Oltjer, R.; Tiirik, K.; Kogermann, K.; Plaas, M.; Tiirats, T.; Aasmae, B.; Krinka, D.; Talpsep, E.; Kadaja, M.; Gerhold, J. M.; Planken, A.; Tover, A.; Merits, A.; Mannik, A.; Ustav, M.
Title: Bovine Colostrum Derived Antibodies Against SARS-CoV-2 Show Great Potential to Serve as a Prophylactic Agent
  • Cord-id: t0pgr4dj
  • Document date: 2021_6_9
  • ID: t0pgr4dj
    Snippet: Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) until now imposes a serious burden to health systems globally. Despite worldwide vaccination, social distancing and wearing masks, the spread of the virus is still ongoing. One of the mechanisms how neutralizing antibodies (NAbs) block virus entry into cells encompasses interaction inhibition between the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and the spike (S) protein of SARS-CoV-2. SARS-CoV-2 specific NAb develop
    Document: Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) until now imposes a serious burden to health systems globally. Despite worldwide vaccination, social distancing and wearing masks, the spread of the virus is still ongoing. One of the mechanisms how neutralizing antibodies (NAbs) block virus entry into cells encompasses interaction inhibition between the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and the spike (S) protein of SARS-CoV-2. SARS-CoV-2 specific NAb development can be induced in the blood of cattle. Pregnant cows produce NAbs upon immunization, and antibodies move into the colostrum just before calving. Here we immunized cows with SARS-CoV-2 S1 receptor binding domain (RBD) protein in proper adjuvant solutions, followed by one boost with SARS-CoV-2 trimeric S protein, and purified immunoglobulins from colostrum. We demonstrate that this preparation indeed blocks interaction between the trimeric S protein and ACE2 in different in vitro assays. Moreover, we describe the formulation of purified immunoglobulin preparation into a nasal spray. When administered to human subjects, the formulation persists on the nasal mucosa for at least 4 hours as determined by a clinical study. Therefore, we are presenting a solution that shows great potential to serve as a prophylactic agent against SARS-CoV-2 infection as an additional measure to vaccination and wearing masks. Moreover, our technology allows for a rapid and versatile adaption for preparing prophylactic treatments against other diseases by using the defined characteristics of antibody movement into the colostrum.

    Search related documents:
    Co phrase search for related documents
    • action site and local delivery: 1
    • action time and administered dose: 1
    • action time and luciferase activity: 1
    • administered dose and low dose subgroup: 1
    • administered dose and luciferase activity: 1, 2
    • administration prior and local delivery: 1